Abstract
Background: Eosinophilic esophagitis (EoE) is increasingly common, but data on phenotypic aspects are still incomplete. Objectives: To describe the clinical, endoscopic, and histopathologic features of a large number of children and adults with EoE across the United States. Methods: This was a multisite single visit registry enrolling subjects aged 6 months to 65 years with EoE. Participants provided responses regarding their medical history, with verification of the diagnosis and history by the study teams. Results: A total of 705 subjects were analyzed (median [interquartile range] age at enrollment 11.2 [6.7-17.7] years, 68.2% male, 87.9% whites). Of these, 67 subjects had concurrent gastrointestinal eosinophilia, with gastric mucosa most common. An age- and race-dependent time gap was present between symptom onset and time of diagnosis (adults and whites with longer gap). Food allergy and atopic dermatitis were associated with a decrease in this gap. Symptoms varied with age (more dysphagia and food impaction in adults) and with race (more vomiting in non-whites). Esophageal rings and strictures at diagnosis were more common in adults, although esophageal eosinophilia was comparable among age groups. Concomitant allergic disease (91%), infectious/immunologic disorders (44%), neurodevelopmental disorders (30%), and failure to thrive (21%) were common. Depression/anxiety increased with age. EoE was reported in 3% of parents and 4.5% of siblings. Conclusions: Gastrointestinal eosinophilia is present in approximately 10% of patients with EoE; the symptom-diagnosis time gap is influenced by age, race, food allergy, and atopic dermatitis; symptoms vary with race; concurrent infectious/immunologic disorders and mental health disorders are common; and the level of esophageal eosinophils is comparable in patients with and without fibrostenotic features.
Original language | English |
---|---|
Pages (from-to) | 1534-1544.e5 |
Journal | Journal of Allergy and Clinical Immunology: In Practice |
Volume | 6 |
Issue number | 5 |
DOIs | |
State | Published - 1 Sep 2018 |
Keywords
- Atopy
- Autoimmune disease
- Eosinophilic colitis
- Eosinophilic esophagitis
- Eosinophilic gastritis
- Eosinophilic gastroenteritis
- Food allergy
- Multisite
- Proton pump inhibitor
- Race
- Registry
Access to Document
Fingerprint
Dive into the research topics of 'Phenotypic Characterization of Eosinophilic Esophagitis in a Large Multicenter Patient Population from the Consortium for Food Allergy Research'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 6, No. 5, 01.09.2018, p. 1534-1544.e5.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Phenotypic Characterization of Eosinophilic Esophagitis in a Large Multicenter Patient Population from the Consortium for Food Allergy Research
AU - Chehade, Mirna
AU - Jones, Stacie M.
AU - Pesek, Robbie D.
AU - Burks, A. Wesley
AU - Vickery, Brian P.
AU - Wood, Robert A.
AU - Leung, Donald Y.M.
AU - Furuta, Glenn T.
AU - Fleischer, David M.
AU - Henning, Alice K.
AU - Dawson, Peter
AU - Lindblad, Robert W.
AU - Sicherer, Scott H.
AU - Abonia, J. Pablo
AU - Sherrill, Joseph D.
AU - Sampson, Hugh A.
AU - Rothenberg, Marc E.
N1 - Funding Information: This work was supported by grants from National Institutes of Health-National Institute of Allergy and Infectious Diseases (NIH-NIAID; U19AI066738 and U01AI066560). The project was also supported by grant numbers UL1 RR-025780 (National Jewish), UL1 TR-000067 (Mount Sinai), UL1 TR-000039 (Arkansas), UL1 TR-000083 (U North Carolina), and UL1 TR-000424 (Johns Hopkins) from the National Center for Research Resources (NCRR), a component of the NIH. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Other funding sources: LaCache Fund for GI Allergic and Immunologic Diseases. Funding Information: Conflicts of interest: M. Chehade received consulting fees from Shire, Regeneron, and Allakos, and research funding from the National Institutes of Health (NIH), Patient-Centered Outcomes Research Institute (PCORI) , Nutricia , Regeneron , and Shire . S. M. Jones is a member of the Research Advisory Board of the Food Allergy Research and Education (FARE); consultant on the scientific advisory board for Aimmune Therapeutics; received grants for clinical trials from Aimmune Therapeutics, DBV Technologies, Astellas, FARE, and National Peanut Board; and received research grant from NIH-NIAID (Immune Tolerance Network), NIH-NIAID (Consortium of Food Allergy Research). She also received payment from EMMES Corporation for Center for Scientific Review (CSR) review/preparation for DBV Technologies. R. D. Pesek reports support through a research training grant as part of the Consortium of Eosinophilic Gastrointestinal Researchers (CEGIR). CEGIR (U54 AI117804) is part of the Rare Disease Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), and is funded through collaboration between NIAID, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and NCATS. CEGIR is also supported by patient advocacy groups including American Partnership for Eosinophilic Disorders (APFED), Campaign Urging Research for Eosinophilic Disease (CURED), and Eosinophilic Family Coalition (EFC). A. Wesley Burks received fees as a member of the NIH Allergy, Immunology, and Transplantation Research Committee (AITC) Review Panel, shareholder in Allertein, from the American Society for Microbiology, as co-editor on food allergy textbook, as Chair and Research Advisory Board for the FARE, and and as a board member of the World Allergy Organization. He also received fees as a consultant for Adept Field Solutions, a consultant and advisory board member for Aimmune Therapeutics, and as a consultant for Astellas Pharma Global Development, Biomerica, Evelo Biosciences/Epiva Biosciences, First Manhattan Co, Genentech, Gerson Lehrman Group (GLG) Research, Insys Therapeutics, Intrommune Therapeutics, Pharmaceutical Product Development (PPD), Regeneron Pharmaceuticals, Sanofi US Services, SRA International, Stallergenes, UKKO, and Valeant Pharmaceuticals North America. He also received research grants from FARE, the NIH, and the Wallace Research Foundation. B. P. Vickery was an employee of Aimmune Therapeutics and had stock options in the company. R. A. Wood has received research grants from the NIH, Astellas, DBV, Aimmune, and HAL Allergy. D. Y. M. Leung has no disclosures relevant to this manuscript. G. T. Furuta is co-founder for EnteroTrack, consultant for Shire, and received royalties from UpToDate. D. M. Fleischer is a nonpaid board member on the National Peanut Board, Food Allergy and Anaphylaxis Connection Team (FAACT) Medical Advisory Board, and FARE Clinical Advisory Board. He or his institution has received fees as a consultant on the Advisory Board for DBV Technologies, Aimmune Therapeutics, Monsanto, Kaleo Pharma, INSYS Therapeutics, BEFORE Brands, and Intrommune. He received research grants from Nestlé Nutrition Institute, DBV Technologies, and Aimmune Therapeutics. He received payment for Continuing Medical Education (CME) lecture and manuscript preparation from Nestle Nutrition Institute, and royalties from UpToDate. A. K. Henning, P. Dawson, and R. W. Lindblad are employees of the EMMES Corporation, which is a Contract Research Organization; EMMES was funded by the NIH to be the Statistical and Clinical Coordinating Center for the Consortium for Food Allergy Research. S. H. Sicherer receives grant support from NIAID/NIH and FARE. He receives royalties from UpToDate and Johns Hopkins University Press. He receives an honorarium as Associate Editor from the American Academy of Allergy, Asthma, and Immunology. J. P. Abonia has received research grants from the Consortium of Eosinophilic Gastrointestinal Disease Researchers (NIH/NIAID U54AI117804), PCORI SC14-1403-11593, NIH/NIAID R01 AI124355-01. J. D. Sherrill has no disclosures relevant to this manuscript. H. A. Sampson is a part-time employee of DBV Technologies (CSO) and has served as a consultant to Allertein Therapeutics, Hycor, and UCB, has received royalties from UpToDate and Elsevier, and funding from NIAID . M. E. Rothenberg is a consultant for Pulm One, Spoon Guru, ClostraBio, Celgene, Shire, Astra Zeneca, GlaxoSmithKline, Allakos, Adare, Regeneron, and Novartis and has an equity interest in the first 4 listed and Immune Pharmaceuticals, and royalties from reslizumab (Teva Pharmaceuticals) and UpToDate. He is also an inventor of patents, owned by Cincinnati Children's. Funding Information: Conflicts of interest: M. Chehade received consulting fees from Shire, Regeneron, and Allakos, and research funding from the National Institutes of Health (NIH), Patient-Centered Outcomes Research Institute (PCORI), Nutricia, Regeneron, and Shire. S. M. Jones is a member of the Research Advisory Board of the Food Allergy Research and Education (FARE); consultant on the scientific advisory board for Aimmune Therapeutics; received grants for clinical trials from Aimmune Therapeutics, DBV Technologies, Astellas, FARE, and National Peanut Board; and received research grant from NIH-NIAID (Immune Tolerance Network), NIH-NIAID (Consortium of Food Allergy Research). She also received payment from EMMES Corporation for Center for Scientific Review (CSR) review/preparation for DBV Technologies. R. D. Pesek reports support through a research training grant as part of the Consortium of Eosinophilic Gastrointestinal Researchers (CEGIR). CEGIR (U54 AI117804) is part of the Rare Disease Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), and is funded through collaboration between NIAID, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and NCATS. CEGIR is also supported by patient advocacy groups including American Partnership for Eosinophilic Disorders (APFED), Campaign Urging Research for Eosinophilic Disease (CURED), and Eosinophilic Family Coalition (EFC). A. Wesley Burks received fees as a member of the NIH Allergy, Immunology, and Transplantation Research Committee (AITC) Review Panel, shareholder in Allertein, from the American Society for Microbiology, as co-editor on food allergy textbook, as Chair and Research Advisory Board for the FARE, and and as a board member of the World Allergy Organization. He also received fees as a consultant for Adept Field Solutions, a consultant and advisory board member for Aimmune Therapeutics, and as a consultant for Astellas Pharma Global Development, Biomerica, Evelo Biosciences/Epiva Biosciences, First Manhattan Co, Genentech, Gerson Lehrman Group (GLG) Research, Insys Therapeutics, Intrommune Therapeutics, Pharmaceutical Product Development (PPD), Regeneron Pharmaceuticals, Sanofi US Services, SRA International, Stallergenes, UKKO, and Valeant Pharmaceuticals North America. He also received research grants from FARE, the NIH, and the Wallace Research Foundation. B. P. Vickery was an employee of Aimmune Therapeutics and had stock options in the company. R. A. Wood has received research grants from the NIH, Astellas, DBV, Aimmune, and HAL Allergy. D. Y. M. Leung has no disclosures relevant to this manuscript. G. T. Furuta is co-founder for EnteroTrack, consultant for Shire, and received royalties from UpToDate. D. M. Fleischer is a nonpaid board member on the National Peanut Board, Food Allergy and Anaphylaxis Connection Team (FAACT) Medical Advisory Board, and FARE Clinical Advisory Board. He or his institution has received fees as a consultant on the Advisory Board for DBV Technologies, Aimmune Therapeutics, Monsanto, Kaleo Pharma, INSYS Therapeutics, BEFORE Brands, and Intrommune. He received research grants from Nestlé Nutrition Institute, DBV Technologies, and Aimmune Therapeutics. He received payment for Continuing Medical Education (CME) lecture and manuscript preparation from Nestle Nutrition Institute, and royalties from UpToDate. A. K. Henning, P. Dawson, and R. W. Lindblad are employees of the EMMES Corporation, which is a Contract Research Organization; EMMES was funded by the NIH to be the Statistical and Clinical Coordinating Center for the Consortium for Food Allergy Research. S. H. Sicherer receives grant support from NIAID/NIH and FARE. He receives royalties from UpToDate and Johns Hopkins University Press. He receives an honorarium as Associate Editor from the American Academy of Allergy, Asthma, and Immunology. J. P. Abonia has received research grants from the Consortium of Eosinophilic Gastrointestinal Disease Researchers (NIH/NIAID U54AI117804), PCORI SC14-1403-11593, NIH/NIAID R01 AI124355-01. J. D. Sherrill has no disclosures relevant to this manuscript. H. A. Sampson is a part-time employee of DBV Technologies (CSO) and has served as a consultant to Allertein Therapeutics, Hycor, and UCB, has received royalties from UpToDate and Elsevier, and funding from NIAID. M. E. Rothenberg is a consultant for Pulm One, Spoon Guru, ClostraBio, Celgene, Shire, Astra Zeneca, GlaxoSmithKline, Allakos, Adare, Regeneron, and Novartis and has an equity interest in the first 4 listed and Immune Pharmaceuticals, and royalties from reslizumab (Teva Pharmaceuticals) and UpToDate. He is also an inventor of patents, owned by Cincinnati Children's. Publisher Copyright: © 2018 American Academy of Allergy, Asthma & Immunology
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Background: Eosinophilic esophagitis (EoE) is increasingly common, but data on phenotypic aspects are still incomplete. Objectives: To describe the clinical, endoscopic, and histopathologic features of a large number of children and adults with EoE across the United States. Methods: This was a multisite single visit registry enrolling subjects aged 6 months to 65 years with EoE. Participants provided responses regarding their medical history, with verification of the diagnosis and history by the study teams. Results: A total of 705 subjects were analyzed (median [interquartile range] age at enrollment 11.2 [6.7-17.7] years, 68.2% male, 87.9% whites). Of these, 67 subjects had concurrent gastrointestinal eosinophilia, with gastric mucosa most common. An age- and race-dependent time gap was present between symptom onset and time of diagnosis (adults and whites with longer gap). Food allergy and atopic dermatitis were associated with a decrease in this gap. Symptoms varied with age (more dysphagia and food impaction in adults) and with race (more vomiting in non-whites). Esophageal rings and strictures at diagnosis were more common in adults, although esophageal eosinophilia was comparable among age groups. Concomitant allergic disease (91%), infectious/immunologic disorders (44%), neurodevelopmental disorders (30%), and failure to thrive (21%) were common. Depression/anxiety increased with age. EoE was reported in 3% of parents and 4.5% of siblings. Conclusions: Gastrointestinal eosinophilia is present in approximately 10% of patients with EoE; the symptom-diagnosis time gap is influenced by age, race, food allergy, and atopic dermatitis; symptoms vary with race; concurrent infectious/immunologic disorders and mental health disorders are common; and the level of esophageal eosinophils is comparable in patients with and without fibrostenotic features.
AB - Background: Eosinophilic esophagitis (EoE) is increasingly common, but data on phenotypic aspects are still incomplete. Objectives: To describe the clinical, endoscopic, and histopathologic features of a large number of children and adults with EoE across the United States. Methods: This was a multisite single visit registry enrolling subjects aged 6 months to 65 years with EoE. Participants provided responses regarding their medical history, with verification of the diagnosis and history by the study teams. Results: A total of 705 subjects were analyzed (median [interquartile range] age at enrollment 11.2 [6.7-17.7] years, 68.2% male, 87.9% whites). Of these, 67 subjects had concurrent gastrointestinal eosinophilia, with gastric mucosa most common. An age- and race-dependent time gap was present between symptom onset and time of diagnosis (adults and whites with longer gap). Food allergy and atopic dermatitis were associated with a decrease in this gap. Symptoms varied with age (more dysphagia and food impaction in adults) and with race (more vomiting in non-whites). Esophageal rings and strictures at diagnosis were more common in adults, although esophageal eosinophilia was comparable among age groups. Concomitant allergic disease (91%), infectious/immunologic disorders (44%), neurodevelopmental disorders (30%), and failure to thrive (21%) were common. Depression/anxiety increased with age. EoE was reported in 3% of parents and 4.5% of siblings. Conclusions: Gastrointestinal eosinophilia is present in approximately 10% of patients with EoE; the symptom-diagnosis time gap is influenced by age, race, food allergy, and atopic dermatitis; symptoms vary with race; concurrent infectious/immunologic disorders and mental health disorders are common; and the level of esophageal eosinophils is comparable in patients with and without fibrostenotic features.
KW - Atopy
KW - Autoimmune disease
KW - Eosinophilic colitis
KW - Eosinophilic esophagitis
KW - Eosinophilic gastritis
KW - Eosinophilic gastroenteritis
KW - Food allergy
KW - Multisite
KW - Proton pump inhibitor
KW - Race
KW - Registry
UR - http://www.scopus.com/inward/record.url?scp=85052477208&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2018.05.038
DO - 10.1016/j.jaip.2018.05.038
M3 - Article
C2 - 30075341
AN - SCOPUS:85052477208
SN - 2213-2198
VL - 6
SP - 1534-1544.e5
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 5
ER -